Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2023 –2030 | |
|
|
USD 0.81 Billion |
| USD 3.48 Billion | |
| % | |
|
Global Urothelial Carcinoma Treatment Market, By Type (Papillary and Flat Carcinoma), Treatment (Chemotherapy, Radiotherapy and Immunotherapy), Diagnostic Test (Urine Cytology, Biopsy, Computed tomography scanning, Ultrasound Imaging, Cystoscopy and Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
According to World Cancer Research Fund International records, bladder cancer is the ninth most common cancer in the world and in the year 2012, around 430,000 new cases were diagnosed. It has been witnessed that at diagnosis, about 70% of cases are non-muscle invasive disease, 20% are at the muscle-invasive stage, and 10% at the advanced stage. About 59% of bladder cancer cases occur in highly developed regions such as North America and Europe. Urothelial cancer's economic and human toll signifies a highly disproportionate health burden.
Data Bridge Market Research analyses a growth rate in the global urothelial carcinoma treatment market in the forecast period 2023-2030. The expected CAGR of global urothelial carcinoma treatment market is tend to be around 20% in the mentioned forecast period. The market was valued at USD 0.81 billion in 2022, and it would grow upto USD 3.48 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 203O
|
|
Base Year
|
2022
|
|
Historic Years
|
2020 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Papillary and Flat Carcinoma), Treatment (Chemotherapy, Radiotherapy and Immunotherapy), Diagnostic Test (Urine Cytology, Biopsy, Computed tomography scanning, Ultrasound Imaging, Cystoscopy and Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Dendreon Pharmaceuticals LLC (U.S.), Eisai Co., Ltd (Japan), Genentech, Inc (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), UroGen Pharma, Inc. (U.S.), Konninklije Philips N.V. (Netherlands), Olympus Corporation (Japan), Pacific Edge (New Zealand), AroCell AB (Sweden), Agilent Technologies Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Urothelial carcinoma is a type of disorder that begins when urothelial cells in the bladder lining changes and grow abnormally leading into the formation of a mass called tumor. It is the most common type of bladder cancer. A person suffering from bladder cancer also have a fair chance of having tumors in ureter, urethra, renal pelvis. The complication occurs when bladder cancers may spread to deeper bladder layers and becomes difficult to control. The typical symptoms of urothelial carcinoma include blood in the urine, pain, irritation in bladder, urination habits changes, edema, night sweats, weight loss and fever.
Drivers
The growing prevalence of bladder cancer across the world supports the market expansion during the forest period. For instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are the leading cancer occurrences around the world. It has also been reported that in 2020, the projected number of new cases of bladder cancer was around 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high occurrence of cancer globally is boosting the market growth.
Chemotherapy is considered as the first-line treatment for urothelial cancer. According to the study published in January 2020 titled "Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis", gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been considered the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC). Thus, this boosts the market growth.
Opportunities
There are recent approvals from major market players that create much opportunities for the market growth. For instance, the urothelial cancer drugs market is likely to be benefitted from better therapies that are being approved by leading drug regulatory organizations. For instance, in April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene for the treatment of advanced or metastatic urothelial carcinoma. Numerous novel treatments are predicted to see approvals, further supporting the growth of the market.
Numerous strategies has been adopted by the major market players which are boosting the market growth. For instance, in June 2020, Pfizer received the U.S. FDA approval for BAVENCIO. It has been approved as the first-line maintenance treatment among patients who are suffering from advanced or metastatic urothelial carcinoma. Additionally, in April 2020, UroGen Pharma received the U.S. FDA approval for mitomycin gel that has been indicated for the treatment of low-grade upper tract urothelial cancer . This creates more opportunities in the market.
Restraints/Challenges
Lack of skilled healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could restrict the growth of the global urothelial carcinoma treatment market during a forecast period.
The huge expenditure of the treatment methods hamper the market growth. The high R&D cost associated with the manufacturing of urothelial cancer drugs, along with increased penetration of generic drugs, is likely to impede the market growth.
This global urothelial carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global urothelial carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments:
The global urothelial carcinoma treatment market is segmented on the basis of treatment, type, diagnostic test, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
Treatment
Diagnostic Test
End-Users
Distribution Channel
The global urothelial carcinoma treatment market is analyzed and market size insights and trends are provided by treatment, type, diagnostic test, distribution channel and end-user as referenced above.
The major countries covered in the global urothelial carcinoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacturers of the product, increasing research and development activities, healthcare expenditure, and skilled professionals in the region.
Asia-Pacific dominates the market due to increased new research and developments on urothelial carcinoma treatment market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global urothelial carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global urothelial carcinoma treatment market.
Key players operating in the global urothelial carcinoma treatment market include:
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTLE
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 EPIO NUMBER
6.1.4 PATENT STRENGTH AND QUALITY
6.1.5 PATENT CLAIMS
6.1.6 PATENT CITATIONS
6.1.7 PATENT LITIGATION AND LICENSING
6.1.8 FILE OF PATENT
6.1.9 PATENT RECEIVED CONTRIES
6.1.10 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOT
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET ACCESS
10.1 10-YEAR MARKET FORECAST
10.2 CLINICAL TRIAL RECENT UPDATES
10.3 ANNUAL NEW FDA APPROVED DRUGS
10.4 DRUGS MANUFACTURER AND DEALS
10.5 MAJOR DRUG UPTAKE
10.6 CURRENT TREATMENT PRACTICES
10.7 IMPACT OF UPCOMING THERAPY
11 R & D ANALYSIS
11.1 COMPARATIVE ANALYSIS
11.2 DRUG DEVELOPMENTAL LANDSCAPE
11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
11.4 THERAPEUTIC ASSESSMENT
11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
11.6 DRUGS AND THERAPIES IN CLINICAL TRIALS
11.7 EMERGING TREATMENT APPROACHES
12 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY TYPE
12.1 OVERVIEW
12.2 PAPILLARY UROTHELIAL CARCINOMA
12.3 FLAT UROTHELIAL CARCINOMA
13 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET , BY GRADE TYPE
13.1 OVERVIEW
13.2 LOW-GRADE BLADDER TUMOR
13.3 HIGH-GRADE BLADDER TUMOR
14 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY NATURE
14.1 OVERVIEW
14.2 INVASIVE NATURE
14.3 NON INVASIVE NATURE
15 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY TREATMENT
15.1 OVERVIEW
15.2 NADOFARAGENE FIRADENOVEC GENE THERAPY
15.3 CHEMOTHERAPY
15.3.1 INTRAVESICAL CHEMOTHERAPY
15.3.1.1. MITOMYCIN-C
15.3.1.2. GEMCITABINE
15.3.1.3. DOCETAXEL
15.3.1.4. VALRUBICIN
15.3.1.5. OTHERS
15.3.2 SYSTEMIC CHEMOTHERAPY
15.3.2.1. 5-FU.
15.3.2.2. CARBOPLATIN.
15.3.2.3. GEMCITABINE.
15.3.2.4. CISPLATIN.
15.3.2.5. PEMETREXED
15.3.2.6. PACLITAXEL.
15.3.2.7. DOXORUBICIN.
15.3.2.8. METHOTREXATE
15.3.2.9. VINBLASTINE
15.3.2.10. OTHERS
15.3.3 OTHERS
15.4 RADIOTHERAPY
15.4.1 EXTERNAL BEAM RADIATION THERAPY (EBRT)
15.4.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)
15.5 IMMUNOTHERAPY
15.5.1 LOCAL THERAPY
15.5.1.1. BACILLUS CALMETTE-GUERIN (BCG)
15.5.1.2. INTERFERON
15.5.1.2.1. ROFERON-A
15.5.1.2.2. INTRON A
15.5.1.2.3. ALFERON
15.5.2 SYSTEMIC THERAPY
15.5.2.1. ATEZOLIZUMAB
15.5.2.2. DURVALUMAB
15.5.2.3. AVELUMAB
15.5.2.4. NIVOLUMAB
15.5.2.5. PEMBROLIZUMAB
15.5.2.6. OTHERS
15.6 TARGETED THERAPY
15.6.1 ERDAFITINIB
15.6.2 ENFORTUMAB
15.6.3 RAMUCIRUMAB
15.6.4 SACITUZUMAB GOVITECAN
15.6.5 OTHERS
15.7 SURGERY
15.7.1 TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT)
15.7.2 URINARY DIVERSION
15.7.3 CYSTECTOMY
15.7.3.1. PARTIAL CYSTECTOMY
15.7.3.2. RADICAL CYSTECTOMY
15.7.4 OTHERS
16 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY DIAGNOSTIC TEST
16.1 OVERVIEW
16.2 BIOPSY
16.3 URETEROSCOPY
16.4 URINE CYTOLOGY
16.5 COMPUTED TOMOGRAPHY SCANNING
16.6 INTRAVENOUS PYELOGRAM (IVP)
16.7 ULTRASOUND IMAGING
16.8 CYSTOSCOPY
16.9 OTHERS
17 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY STAGES
17.1 OVERVIEW
17.2 STAGE 0
17.3 STAGE I
17.4 STAGE II
17.5 STAGE III
17.6 STAGE IV
18 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 SOLID
18.2.1.1. PILL
18.2.1.2. CAPSULE
18.2.1.3. TABLETS
18.2.1.4. OTHERS
18.2.2 LIQUID
18.2.3 OTHERS
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 OTHERS
18.4 OTHERS
19 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.3 FEMALE
20 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITAL
20.2.1 BY TYPE
20.2.1.1. PUBLIC
20.2.1.2. PRIVATE
20.2.2 BY LEVEL
20.2.2.1. LEVEL 1
20.2.2.2. LEVEL 2
20.2.2.3. LEVEL 3
20.3 SPECIALTY CLINICS
20.4 HOME HEALTHCARE
20.5 DIAGNOSTIC CENTERS
20.6 RESEARCH INSTITUTES
20.7 OTHERS
21 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 ONLINE PHARMACY
21.3.2 HOSPITALS PHARMACY
21.4 OTHERS
22 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY REGION
GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 ITALY
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 TURKEY
23.2.8 BELGIUM
23.2.9 NETHERLANDS
23.2.10 SWITZERLAND
23.2.11 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 AUSTRALIA
23.3.6 SINGAPORE
23.3.7 THAILAND
23.3.8 MALAYSIA
23.3.9 INDONESIA
23.3.10 PHILIPPINES
23.3.11 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 SAUDI ARABIA
23.5.3 UAE
23.5.4 EGYPT
23.5.5 ISRAEL
23.5.6 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
25 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, COMPANY PROFILE
25.1 ASTELLAS PHARMA US, INC. + SEAGEN INC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 MERCK SHARP & DOHME LLC
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 JANSSEN BIOTECH, INC. + PHARMACYCLICS LLC (ABBVIE COMPANY)
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 EMD SERONO, INC.
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 GILEAD SCIENCES, INC.
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 GENENTECH, INC. (F. HOFFMANN-LA ROCHE LTD )
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 UROGEN PHARMA, LTD.
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 ACERTA PHARMA BV
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 BRISTOL-MYERS SQUIBB COMPANY
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 GSK PLC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 INCYTE BIOSCIENCES DISTRIBUTION B.V.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 ASTRAZENECA
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 HIKMA PHARMACEUTICALS PLC + JUNSHI BIOSCIENCES
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIF IED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.